Press Releases

CRANFORD, N.J. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021 .

Looking to Next Step – Acquisition Opportunities CRANFORD, N.J. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals , Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced the results of its rights offering following the expiration of the subscription period on October 9, 2020 at 5:00 p.m.

CRANFORD, N.J. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously-announced rights offering to raise proceeds of approximately $43 million .  The proceeds from the

CRANFORD, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”) originally scheduled to be held on Thursday, September 17, 2020 , has been postponed and will now

CRANFORD, N.J. , Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights offering to existing shareholders whereby the Company intends to distribute one transferable

CRANFORD, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits preservation plan (the “Section 382 Rights Plan”) designed to protect the availability of Enzon’s net

PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.

PISCATAWAY, NJ -- (Marketwired) -- 04/23/13 -- Enzon Pharmaceuticals, Inc.

PISCATAWAY, NJ -- (Marketwire) -- 03/18/13 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth quarter and full year 2012.

PISCATAWAY, NJ -- (Marketwire) -- 12/17/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that its Board of Directors has retained Lazard to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets, or a sale of the Company.